Navigation Links
Anti-Retroviral Therapies Associated with Reduced Infections in HIV-Infected Children

Since the introduction of highly active antiretroviral therapies, there has been a substantial reduction of opportunistic infections and other infections in HIV-infected children,// such as pneumonia and tuberculosis, according to a study.

The human immunodeficiency virus (HIV) epidemic has spurred the development of new antiretroviral, immune, and vaccine-based therapies geared to block transmission, prevent disease progression, and prolong the survival of individuals who are HIV positive, according to background information in the article. Highly active antiretroviral therapy (HAART) has dramatically decreased rates of AIDS-related opportunistic infections (infections caused by an organism capable of causing disease in a host whose resistance is lowered, e.g., by other diseases or by drugs) and deaths in adults. Although HAART has dramatically decreased illness and death in HIV-infected infants, children, and adolescents in the United States, no studies comparing the incidence of opportunistic and other related infections before and during the HAART era have been conducted.

Philimon Gona, Ph.D., of the Harvard School of Public Health and Boston University, Boston, and colleagues estimated the rates for the first occurrence of 29 targeted opportunistic and other related infections between Jan. 1, 2001, and Dec. 31, 2004, in HIV-infected infants, children, and adolescents to compare the rates in the HAART era to those of the pre-HAART era. The study included 2,767 children enrolled between Sept. 15, 2000, and Dec. 31, 2004, with information entered in the database up to August 1, 2005, when data analysis was conducted. The pre-HAART era comparison population included 3,331 children enrolled in 13 Pediatric AIDS Clinical Trials Group (PACTG) protocols from October 1988 to August 1998.

Seventy-five percent of the children were enrolled in 2000 and 2001. Overall, 553 first episodes of a specific infection occurred among 395 (14 percen t) of the study participants. The incidence rates (IRs) per 100 person-years for the 4 most common first-time infections were bacterial pneumonia (IR, 2.15), herpes zoster (IR, 1.11), dermatophyte infections (IR, 0.88), and oral candidiasis (IR, 0.93). Infection rates were significantly lower than those reported in the PACTG in the pre-HAART era: bacterial pneumonia (IR, 11.1), bacteremia (IR, 3.3), herpes zoster (IR, 2.9), oral candidiasis (IR, 1.2) and tuberculosis (IR, 0.2).

“Despite these current advances due to HAART, some HIV-infected children continue to develop opportunistic infections. Some children fail to respond to antiretroviral therapy as a result of viral resistance, poor adherence, or inability to tolerate complex treatment regimens. Furthermore, prophylactic [preventive] therapies are not fully effective and poor adherence can further reduce their efficacy. Drug interactions, complex dosing schedules, adverse effects, and high costs can further limit the efficacy of these therapies. Although these issues do present challenges, our findings demonstrate a substantial reduction in the incidence of several opportunistic infections in HIV-infected children since the introduction of HAART therapy,” the authors write.

(Source: Newswise)
'"/>




Related medicine news :

1. Anti-Retrovirals in Africa, not a distant dream
2. Anti-Retrovirals Capable of Halting Mental Illness in HIV Patients
3. New Way to "See" Genes, Evaluate Effectiveness of Gene Therapies Discovered
4. Preventive Therapies Found to be More Effective in Managing Migraines
5. Ayurvedic Therapies Cashing In On Medical Tourism
6. Immune-Boosting Therapies Of No Use In Preventing Miscarriage
7. Non Hormonal Therapies for Menopause Not Proved to be Effective
8. Need for More Talking Therapies for Treating Depression
9. Are Alternative Therapies A Reliable Alternative?
10. Special Behavioral Therapies made Women more likely to Attempt Suicide
11. Alternative Therapies May Not Ease Menopause Symptoms
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/26/2017)... ... 26, 2017 , ... IndustryArchive.Org . is announcing a new way for ... will now only pay for B.A.N.T. quality sales leads based on the Sellers decision ... the new reality that B2B buyers are controlling the sales process via the Internet ...
(Date:2/26/2017)... , ... February 26, 2017 , ... ... disease (PD) in persons with a specific LRRK2 mutation, according to a study ... Previous studies have provided evidence of a link between pesticides and incidence of ...
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the official ... (ILTM) show in Cannes (France), XO Private has initiated a second print-run of its ... measures almost a metre across when open, weighs in at more than six kilos, ...
(Date:2/24/2017)... ... 24, 2017 , ... The Smart Machine Age is here, and it’s disrupting ... percent of all jobs in the United States may be taken over by technology ... the aggressive know-it-all who steamrolls over colleagues is drawing to a close. Success will ...
(Date:2/24/2017)... Australia (PRWEB) , ... February 24, 2017 , ... The ... AU) offers Erik Schanssema ’s true account of his paramedic experiences. Schanssema describes ... stress disorder and his attempts to overcome them. , Schanssema, initially unsure of ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... REDWOOD CITY, Calif., Feb. 23, 2017 Nevro Corp. ... innovative evidence-based solutions for the treatment of chronic pain, today ... ended December 31, 2016. 2016 Accomplishment & ... the full year 2016, an increase of 228% as reported, ... million for 2016, an increase of 612% over the prior ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... Strategies - 2016" report to their offering. ... The latest research Oesophageal Cancer ... and benchmarks in the global Oesophageal Cancer market. The ... are the key drugs marketed for Oesophageal Cancer and their clinical ...
(Date:2/23/2017)... , Feb. 23, 2017 Regulus ... the discovery and development of innovative medicines targeting microRNAs, ... year 2016 financial results on Thursday, March 2, 2017 ... a conference call and webcast on March 2, 2017 ... and full year 2016 financial results and provide a ...
Breaking Medicine Technology: